CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

An open-label, intermediate size, expanded access study of rimegepant in the acute treatment of migraine (NCT03934086)

Study title/design: An open-label, intermediate size, expanded access study of rimegepant in the acute treatment of migraine (NCT03934086) Trial NCT03934086 Aim To allow patients who completed any other rimegepant clinical study to have access to rimegepant while collecting ongoing safety data. Study design Adults (> 18 years) treated with rimegepant 75 mg tablet. Patient population …

Read more »

A Phase 2/3, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant in migraine prevention (NCT03732638)

Study title/design: A Phase 2/3, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant in migraine prevention (NCT03732638) Trial NCT03732638 Aim To evaluate the efficacy and safety of rimegepant in patients with migraine Study design Study of patients aged > 18 years randomised to rimegepant 75 mg tablet or placebo for 12 weeks …

Read more »

A Phase 2 double-blind, placebo controlled crossover trial of rimegepant for treatment of refractory trigeminal neuralgia (NCT03941834)

Study title/design: A Phase 2 double-blind, placebo controlled crossover trial of rimegepant for treatment of refractory trigeminal neuralgia (NCT03941834) Trial NCT03941834 Aim To evaluate the efficacy of rimegepant compared to placebo in patients with treatment refractory trigeminal neuralgia (TN). Study design Adults (> 18 years) randomised to rimegepant 75 mg tablet or placebo. Patient population …

Read more »

Phase 3: double-blind, randomised, placebo-controlled, safety and efficacy trial of BHV-3000 (rimegepant) for the acute treatment of migraine (Study 301)

Rimegepant (BVH-3000) Study title/design: Phase 3: double-blind, randomised, placebo-controlled, safety and efficacy trial of BHV-3000 (rimegepant) for the acute treatment of migraine (Study 301) Trial NCT03235479: https://clinicaltrials.gov/ct2/show/NCT03235479?term=rimegepant&draw=1&rank=5 Aim To compare the efficacy of BHV-3000 (rimegepant) versus placebo in patients with acute migraines Study design A total of 1162 patients were randomised to rimegepant 75 mg …

Read more »

Phase 3: double-blind, randomised, placebo-controlled, safety and efficacy trial of BHV-3000 (rimegepant) for the acute treatment of migraine (Study 302)

Rimegepant (BVH-3000) Study title/design: Phase 3: double-blind, randomised, placebo-controlled, safety and efficacy trial of BHV-3000 (rimegepant) for the acute treatment of migraine (Study 302) Trial NCT03237845: https://clinicaltrials.gov/ct2/show/NCT03237845?term=rimegepant&rank=1 Aim To compare the efficacy of BHV-3000 (rimegepant) versus placebo in patients with acute migraines Study design A total of 1186 patients were randomised to rimegepant 75 mg …

Read more »

A multicentre, open label long-term safety study of BHV3000 in the acute treatment of migraine

Rimegepant (BVH-3000) Study title/design: A multicentre, open label long-term safety study of BHV3000 in the acute treatment of migraine Trial NCT03266588: https://clinicaltrials.gov/ct2/show/NCT03266588?term=rimegepant&rank=3 Aim To evaluate the safety and tolerability of rimegepant 75 mg oral tablet Study design 1909 patients enrolled in the single group assessment of rimegepant Patient population Patients 18 years and older with: …

Read more »

Phase 3, double-blind, randomised, placebo controlled, safety and efficacy trial of BHV-3000 (rimegepant) orally disintegrating tablet (ODT) for the acute treatment of migraine (Study 303)

Rimegepant (BVH-3000) Study title/design: Phase 3, double-blind, randomised, placebo controlled, safety and efficacy trial of BHV-3000 (rimegepant) orally disintegrating tablet (ODT) for the acute treatment of migraine Trial NCT03461757: https://clinicaltrials.gov/ct2/show/NCT03461757?term=rimegepant&rank=2 Aim To compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in patients with acute migraines Study design 1466 patients were randomised to rimegepant 75 …

Read more »